The durability data significantly de-risks CTX310 and the broader in vivo cardiovascular gene editing platform. Traders should watch for the Phase 1b update in H2 2026, which could provide further efficacy and safety data in severe hypertriglyceridemia patients. The NEJM publication adds credibility and may attract new institutional interest.
Price Chart
Executive Summary
CRISPR Therapeutics presented one-year durability data from its Phase 1a trial of CTX310, an in vivo CRISPR/Cas9 gene editing therapy targeting ANGPTL3. At the highest dose, mean reductions from baseline were 79% for ANGPTL3, 48% for triglycerides, and 53% for LDL, sustained through one year with no new safety signals. The data were simultaneously published in the New England Journal of Medicine, supporting the potential for a one-time infusion to durably lower lipids and advancing the program into Phase 1b with an update expected in H2 2026.
Key Facts
- Phase 1a data for CTX310 showed mean reductions of 79% (ANGPTL3), 48% (triglycerides), and 53% (LDL) at the highest dose (0.8 mg/kg) sustained through one year.
- Maximum reductions at the highest dose were 89% for ANGPTL3, 78% for triglycerides, and 84% for LDL.
- No treatment-related serious adverse events, no ≥Grade 3 liver transaminase changes, and no new treatment-related safety events during extended follow-up.
- Data published simultaneously in the New England Journal of Medicine.
- Phase 1b trial is ongoing with an update on severe hypertriglyceridemia patients expected in H2 2026.
Financial Impact
Positive catalyst for a mid-cap biotech with a $5.7B market cap; first-in-class in vivo gene editing durability data de-risks the program and supports valuation expansion.
Risk Factors
- Phase 1b data could show reduced efficacy or unexpected safety signals in a larger, more diverse patient population.
- Competition from other ANGPTL3-targeting therapies (e.g., antisense, monoclonal antibodies) could limit commercial uptake.
- Regulatory path for a one-time gene editing therapy is uncertain and may require long-term follow-up data.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3352748 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | Insider Cluster | $50.50 | awaiting T+20 | — | $49.01 (+2.95%) |
Oct 19, 2026 7d ago | 8-K | $49.88 | awaiting T+20 | — | $49.01 (−1.74%) |
Oct 16, 2026 10d ago | Insider Cluster | $50.04 | awaiting T+20 | — | $49.01 (−2.06%) |
Oct 16, 2026 10d ago | Insider Cluster | $50.04 | awaiting T+20 | — | $49.01 (+2.06%) |
Oct 15, 2026 11d ago | Insider Cluster | $49.25 | awaiting T+20 | — | $49.01 (−0.49%) |
Oct 14, 2026 12d ago | 144 | $51.52 | awaiting T+20 | — | $49.01 (−4.87%) |
Oct 6, 2026 20d ago | 144 | $52.35 | awaiting T+20 | — | $49.01 (−6.38%) |
Sep 24, 2026 4w ago | Insider Cluster | $54.23 $49.39 | ▲ +8.92% | ▲ +7.45% | $49.01 (+9.63%) |
Aug 28, 2026 8w ago | Press Release | $57.72 $54.23 | ▼ −6.05% | ▼ −6.56% | $49.01 (−15.09%) |
Aug 3, 2026 12w ago | Press Release | $53.07 $56.82 | ▲ +7.07% | ▲ +8.30% | $49.01 (−7.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers